23andMe Newsroom

23andMe to Report Q1 FY2025 Financial Results

GlobeNewswire32minutes ago

23andMe In Collaboration With 20 Lung Cancer Advocacy Organizations, Announced A New Study To Help Advance Research In Lung Cancer

BenzingaJul 25 07:36 ET

23andMe to Offer Free Blood Testing for Members in Pilot Program

MT NewswiresJun 28 09:12 ET

Express News | 23Andme and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel

ReutersJun 28 07:00 ET

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

26andMeJun 28 00:00 ET

Looking Into 23andMe Holding's Recent Short Interest

BenzingaJun 12 15:15 ET

Sector Update: Health Care Stocks Retreat Monday Afternoon

MT NewswiresJun 10 13:56 ET

Express News | Canada and UK Privacy Authorities Have Launched Joint Investigation Into 23Andme Data Breach - Canada Authority

ReutersJun 10 10:11 ET

Street Color: 23andMe Faces Joint Probe From UK Information Commissioner's Office, Canada's Privacy Commissioner Office Over 2023 Data Breach

MT NewswiresJun 10 10:08 ET

23andMe Launches New Genetic Report on Bipolar Disorder

26andMeJun 5 00:00 ET

Why 23andMe Stock Tumbled 10% on Tuesday

Yahoo FinanceJun 4 12:48 ET

Express News | 23Andme and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community

ReutersJun 4 07:00 ET

23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community

26andMeJun 4 00:00 ET

Express News | 23Andme Holding Co.: Tumor Cd200 Is Emerging as a Potential Biomarker Associated With 23Me-00610 Monotherapy Efficacy

ReutersJun 3 08:02 ET

Express News | 23Andme Holding Co.: 23Me-00610 Monotherapy Continues to Demonstrate Acceptable Safety and Tolerability

ReutersJun 3 08:02 ET

Express News | 23Andme Holding Co.: 23Me-00610 Monotherapy Demonstrates Preliminary Evidence of Clinical Benefit, Including One Confirmed Partial Response

ReutersJun 3 08:02 ET

Express News | 23Andme Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23Me-00610, Targeting Cd200R1, at the 2024 Asco Annual Meeting

ReutersJun 3 08:00 ET

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, Targeting CD200R1, at the 2024 ASCO Annual Meeting

26andMeJun 3 00:00 ET

23andMe | 10-K: Annual report

SEC announcementMay 30 16:12 ET · Announcements

Largest Study on the LRRK2 Variant Leads to Discoveries About Health, Ancestry, and History

26andMeMay 29 00:00 ET